X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
KRM-II-81 is an orally bioavailable imidazodiazepines that acts as a GABA-A receptor potentiator (GABAkine). It is being developed for the treatment of pain.
Lead Product(s): KRM-II-81
Therapeutic Area: Neurology Product Name: KRM-II-81
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
The compounds described in these articles were efficacious as anticonvulsants and the most characterized of these, KRM-II-81, KPP-III-34, displayed robust activity in more advanced anti-seizure models. All compounds were effective without producing sedative effects.
Lead Product(s): KRM-II-81
Therapeutic Area: Neurology Product Name: KRM-II-81
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
KRM-II-81 analogs enhances the GABAergic neurotransmission and function as orally-bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation.
Lead Product(s): KRM-II-81
Therapeutic Area: Neurology Product Name: KRM-II-81
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
GABAkine, KRM-II-81, has been shown to be effective in relieving acute, chronic, and neuropathic pain without tolerance development. KRM-II-81 preferentially bound to specific subtypes of GABAA receptors to inhibit pain sensory neurons in the spinal dorsal root ganglia.
Lead Product(s): KRM-II-81
Therapeutic Area: Neurology Product Name: KRM-II-81
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute for Neurological Disorders and Stroke
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 05, 2022
Details:
KRM-II-81 has a preclinical profile predicting efficacy against pharmacoresistant epilepsies, traumatic brain injury, and neuropathic pain. KRM-II-81 also produces anxiolytic- and antidepressant-like effects in rodent models.
Lead Product(s): KRM-II-81
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: KRM-II-81
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes on Drug Abuse
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
RespireRx Pharmaceuticals has entered into a patent license agreement for GABAA receptor neuromodulator intellectual property from UWM Research Foundation.
Lead Product(s): KRM-II-81
Therapeutic Area: Neurology Product Name: KRM-II-81
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: RespireRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
